OBJECTIVES: Per- and polyfluoroalkyl substances (PFASs) are a large group of persistent synthetic chemicals widely used commercially. They accumulate increasingly in all environmental components and enter the organisms, including humans. Some of them are associated with the risk of harm to health, among others with metabolic disorders. To test the associations between blood serum levels of PFASs and blood lipid profile as well as metabolic syndrome, we linked human biomonitoring with the Czech Health Examination Survey (CZ-EHES) conducted in 2019. METHODS: A total of 168 participants of the CZ-EHES survey aged 25-64 years were examined including anthropometrical data and analyses for serum PFAS and blood lipid levels. Extended model approach in multiple linear regression models was used for identification of the associations between serum levels of 11 PFASs and lipid profile components. The relation between PFAS serum levels and metabolic syndrome prevalence was tested using a logistic regression model. RESULTS: Six PFASs were detected over the limit of quantification in at least 40% cases and were examined in subsequent analyses: perfluorodecanoic acid (PFDA), perfluorohexane sulfonic acid (PFHxS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorooctane sulfonic acid (PFOS), perfluoroundecanoic acid (PFUdA). The most dominant was PFOS with the mean value amounting to 4.81 ng/ml. After adjusting for potential confounders, we found a significant positive association between serum PFHxS and blood total cholesterol (p = 0.005) as well as LDL-cholesterol (p = 0.008). Significant positive association was also found between PFDA and HDL-cholesterol levels (p = 0.010). No significant associations were detected between PFASs and triglycerides, and between PFASs and metabolic syndrome. CONCLUSIONS: We found some evidence of a significant association between blood serum PFAS levels and blood cholesterol levels. Our results did not confirm an association between serum PFASs and the metabolic syndrome prevalence.

3rd Faculty of Medicine Charles University Prague Czech Republic

National Institute of Public Health Prague Czech Republic

Zobrazit více v PubMed

Wang Z, Cousins IT, Scheringer M, Hungerbuehler K. Hazard assessment of fluorinated alternatives to long-chain perfluoroalkyl acids (PFAAs) and their precursors: Status quo, ongoing challenges and possible solutions. Environ Int. 2015;75:172-9. PubMed DOI

Fromme H, Tittlemier SA, Völkel W, Wilhelm M, Twardella D. Perfluorinated compounds - Exposure assessment for the general population in western countries. Int J Hyg Environ Health. 2009;212(3):239-70. PubMed DOI

Sunderland EM, Hu XC, Dassuncao C, Tokranov AK, Wagner CC, Allen JG. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects J Expo Sci Environ Epidemiol. 2019;29(2):131-47. PubMed DOI

Lin CY, Chen PC, Lin YC, Lin LY. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. Diabetes Care. 2009;32(4):702-7.

Dong GH, Tung KY, Tsai CH, Liu MM, Wang D, Liu W, et al. Serum polyfluoroalkyl concentrations, asthma outcomes, and immunological markers in a case-control study of Taiwanese children. Environ Health Perspect. 2013;121(4):507-13. PubMed DOI

Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect. 2010;118(2):197-202. PubMed DOI

Liu HS, Wen LL, Chu PL, Lin CY. Association among total serum isomers of perfluorinated chemicals, glucose homeostasis, lipid profiles, serum protein and metabolic syndrome in adults: NHANES, 2013-2014. Environ Pollut. 2018;232:73-9.

Blake BE, Fenton SE. Early life exposure to per- and polyfluoroalkyl substances (PFAS) and latent health outcomes: A review including the placenta as a target tissue and possible driver of peri- and postnatal effects. Toxicology. 2020;443:152565. doi: 10.1016/j.tox.2020.152565. PubMed DOI

Fu Y, Wang T, Fu Q, Wang P, Lu Y. Associations between serum concentrations of perfluoroalkyl acids and serum lipid levels in a Chinese population. Ecotoxicol Environ Saf. 2014;106:246-52. PubMed DOI

He X, Liu Y, Xu B, Gu L, Tang W. PFOA is associated with diabetes and metabolic alteration in US men: National Health and Nutrition Examination Survey 2003-2012. Sci Total Environ. 2018;625:566-74. PubMed DOI

Yang Q, Guo X, Sun P, Chen Y, Zhang W, Gao A. Association of serum levels of perfluoroalkyl substances (PFASs) with the metabolic syndrome (MetS) in Chinese male adults: A cross-sectional study. Sci Total Environ. 2018;621:1542-9. PubMed DOI

Christensen KY, Raymond M, Meiman J. Perfluoroalkyl substances and metabolic syndrome. Int J Hyg Environ Health. 2019;222(1):147-53. PubMed DOI

Lin CY, Leed HL, Hwang YT, Su TC. The association between total serum isomers of per- and polyfluoroalkyl substances, lipid profiles, and the DNA oxidative/nitrative stress biomarkers in middle-aged Taiwanese adults. Environ Res. 2020;182:109064. doi: 10.1016/j.envres.2019.109064. PubMed DOI

Yang Q, Guo X, Chen Y, Zhang W, Ren J, Wang J, et al. Blood levels of perfluoroalkyl substances (PFASs), elements and their associations with metabolic syndrome (MetS) in Chinese male adults mediated by metabolic-related risk factors. Sci Total Environ. 2020;742:140595. doi: 10.1016/j.scitotenv.2020.140595. PubMed DOI

Das KP, Wood CR, Lin MT, Starkov AA, Lau C, Wallace KB, et al. Perfluoroalkyl acids-induced liver steatosis: Effects on genes controlling lipid homeostasis. Toxicology. 2017;378:37-52. PubMed DOI

Fragki S, Dirven H, Fletcher T, Grasl-Kraupp B, Bjerve Gützkow K, Hoogenboom R, et al. Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not? Crit Rev Toxicol. 2021;51(2):141-64. PubMed DOI

Qi W, Clark JM, Timme-Laragy AR, Park Y. Per- and polyfluoroalkyl substances and obesity, type 2 diabetes and non-alcoholic fatty liver disease: a review of epidemiologic findings. Toxicol Environ Chem. 2020;102(1-4):1-36. PubMed DOI

Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679-89. DOI

Jain RB, Ducatman A. Roles of gender and obesity in defining correlations between perfluoroalkyl substances and lipid/lipoproteins. Sci Total Environ. 2019;653:74-81. DOI

Liu H, Hu W, Li X, Hu F, Xi Y, Su Z, et al. Do perfluoroalkyl substances aggravate the occurrence of obesity-associated glucolipid metabolic disease? Environ Res. 2021;202:111724. doi: 10.1016/j.envres.2021.111724. DOI

Sochorová L, Hanzlíková L, Černá M, Drgáčová A, Fialová A, Švarcová A, et al. Perfluorinated alkylated substances and brominated flame retardants in serum of the Czech adult population. Int J Hyg Environ Health. 2017;220(2 Pt A)):235-43. DOI

Černá M, Pinkr Grafnetterová A, Dvořáková D, Pulkrabová J, Malý M, Janoš T, et al. Biomonitoring of PFOA, PFOS and PFNA in human milk from Czech Republic, time trends and estimation of infant's daily intake. Environ Res. 2020;188:109763. doi:10.1016/j.envres.2020.109763. DOI

Kuulasmaa K, Tolonen H, Koponen P, Kilpeläinen K, Avdicová M, Broda G, et al. An overview of the European Health Examination Survey Pilot Joint Action. Arch Public Health. 2012;70(1):20. doi: 10.1186/0778-7367-70-20. DOI

European Health Examination Survey. Guidelines for health examination surveys [Internet]. Helsinki: Finnish Institute for Health and Welfare [cited 2023 Jan 12]. Available from: https://ehes.info/manuals.htm.

International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome [Internet]. Brussels: IDF; 2006 [cited 2023 Feb 23]. Available from: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81-S90. DOI

Pálešová N, Maitre L, Stratakis N, Řiháčková K, Pindur A, Kohoutek J, et al. Firefighters and the liver: Exposure to PFAS and PAHs in relation to liver function and serum lipids (CELSPAC-FIREexpo study). Int J Hyg Environ Health. 2023;252:114215. doi: 10.1016/j.ijheh.2023.114215. DOI

Fisher M, Arbuckle TE, Wade M, Haines DA. Do perfluoroalkyl substances affect metabolic function and plasma lipids?-Analysis of the 2007-2009, Canadian Health Measures Survey (CHMS) Cycle 1. Environ Res. 2013;121:95-103. DOI

Lin TW, Chen MK, Lin CC, Chen MH, Tsai MS, Chan DC, et al. Association between exposure to perfluoroalkyl substances and metabolic syndrome and related outcomes among older residents living near a Science Park in Taiwan. Int J Hyg Environ Health. 2020;230:113607. doi: 10.1016/j.ijheh.2020.113607. DOI

Zare Jeddi M, Dalla Zuanna T, Barbieri G, Fabricio ASC, Daprà F, Fletcher T, et al. Associations of perfluoroalkyl substances with prevalence of metabolic syndrome in highly exposed young adult community residents - a cross-sectional study in Veneto Region, Italy. Int J Environ Res Public Health. 2021;18(3):1194. doi: 10.3390/ijerph18031194. DOI

Andersen ME, Hagenbuch B, Apte U, Corton JC, Fletcher T, Lau C, et al. Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms. Toxicology. 2021;459:152845. doi: 10.1016/j.tox.2021.152845. DOI

Bjork JA, Butenhoff JL, Wallace KB. Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology. 2011;288(1-3):8-17. DOI

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. DOI